Welcome to our dedicated page for AI / ML Innovations news (Ticker: AIMLF), a resource for investors and traders seeking the latest updates and insights on AI / ML Innovations stock.
AI/ML Innovations Inc. (AIMLF) is a pioneering company in the artificial intelligence (AI) and machine learning (ML) sectors, dedicated to acquiring and advancing technologies that address critical societal needs. Established to capitalize on the burgeoning fields of AI and ML, the company focuses on emerging digital health and wellbeing solutions that leverage AI, cloud computing, and digital platforms to revolutionize healthcare management.
AI/ML Innovations Inc. is committed to transforming healthcare through strategic partnerships and innovative initiatives. Its majority-owned subsidiary, Health Gauge Inc., is at the forefront of health tech innovation. Health Gauge has developed the ‘Follow Your Heart’ smartwatch, a wellness tool that uses proprietary AI PrecisionPulse Neural Network measurement technology to provide non-invasive, medical-grade accurate blood pressure readings. This product is a significant step forward in addressing the hypertension epidemic, offering users convenient and precise health monitoring.
In addition to consumer products, AI/ML Innovations Inc. supports healthcare innovators and researchers with advanced tools like The Pulse Guru, a smart sensor wearable that offers unparalleled access to raw ECG and PPG signal data. This device is instrumental for professionals needing detailed cardiovascular insights.
The company’s strategic growth also includes a recent acquisition of Naiad Labs Inc.’s product division, integrating the Long ECG Neural Net, which drastically reduces the time needed to label long ECGs, enhancing accuracy and efficiency in cardiovascular diagnostics.
AI/ML Innovations Inc. continues to expand its technological footprint with the launch of NeuralCloud Solutions Incorporated, a subsidiary focused on merging smart sensor technology with digital health. The company aims to make high-quality personal biometric data accessible to individuals globally, supported by robust AI and neural network technologies.
AI/ML Innovations Inc. trades on the Canadian Securities Exchange under the symbol AIML, the OTCQB Venture Market under AIMLF, and the Frankfurt Stock Exchange under 42FB. For more information, visit the company's website.
AI/ML Innovations Inc. (CSE:AIML; OTCQB:AIMLF) announced its failure to file required audited annual financial statements for the year ending April 30, 2022, by the August 28, 2022 deadline, resulting in a default under National Instrument 51-102. The British Columbia Securities Commission has issued a management cease trade order (MCTO) which restricts insider trading but does not affect general shareholder trading. The company is actively working to rectify this situation and plans to complete required filings by October 28, 2022.
AI/ML Innovations Inc. (CSE:AIML; OTCQB:AIMLF) has applied for a Management Cease Trade Order (MCTO) from the British Columbia Securities Commission due to the inability to file audited financial statements by the deadline of August 28, 2022. The delays are attributed to the acquisition of Tech2Heal SAS and the need for additional financial documentation to comply with IFRS. The company expects to file the required documents by October 28, 2022. The MCTO, if granted, will restrict trading of shares by the CEO and CFO but will not affect general public trading.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) announced a second pilot study for its Alakin healthcare management platform, launching in Paris, France. This study targets Parkinson's disease, affecting 200,000 individuals in France. Alakin features a user-friendly clinical dashboard and a mobile app for patient interaction, available in five languages. The platform aims to enhance productivity in healthcare settings through customizable care pathways and is set to deploy in various regions, including North America. The trial will integrate digital biomarkers for monitoring patient progress.
AI/ML Innovations Inc. announces the successful results of its Annual General Meeting held on July 27, 2022. A total of 5,412,712 common shares were voted, representing 15.5% of issued shares, achieving quorum. Key resolutions passed include the election of 4 Directors: Tim Daniels, Nick Watters, Randy Duguay, and Bruce Matichuk, the appointment of Baker Tilly Canada as auditors, and the approval of the Company's Stock Option Plan. For more details, shareholders can refer to the Company's profile on SEDAR.
AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) announces the upcoming launch of Alakin, a comprehensive healthcare management platform developed by its subsidiary Tech2Heal. This SaaS solution, built on FHIR standards, aims to improve patient engagement and optimize workflows in healthcare settings. A pilot study will commence at a 30,000-patient facility in Paris, with full deployment planned for August 2022. Alakin will streamline patient care processes, potentially leading to significant time and cost savings for healthcare providers.
AI/ML Innovations Inc. (CSE:AIML; OTCQB:AIMLF) announced that its subsidiary, Tech2Heal SAS, has been selected as a finalist in the prestigious i-Nov Innovation Contest. This recognition highlights the innovative potential of its Qookka digital therapy for mental health disorders, with less than 10% of entries making the cut. The contest, backed by the Programme d'Investissements d'Avenir in France, offers up to €5M in co-financing for winners. Qookka utilizes advanced AI algorithms and digital biomarkers for enhanced patient support and monitoring.
AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) announced a marketing services agreement with Octagon Media Corp to enhance its digital media presence. The contract, lasting three months, involves monthly payments of US$25,000 and the issuance of 500,000 stock options at CAD$0.20. Additionally, the company granted 800,000 options to management at the same exercise price. Through strategic partnerships and a focus on AI and ML technologies, AI/ML aims to drive growth in the healthcare sector.
AI/ML Innovations Inc. announced a License Agreement with MedWatch Technologies, Inc. to utilize patented health management technology and AI software for diabetes monitoring solutions. MedWatch will pay Health Gauge an annual fee of US$120,000 plus a 2% royalty on gross sales. With diabetes-related medical costs in the US at $327 billion annually, the partnership aims to improve patient outcomes through non-invasive monitoring tools. The agreement spans an initial term of 7 years, with a US$2 million termination fee.
AI/ML Innovations Inc. announced a license agreement with MedWatch Technologies for its patented health management technology, targeting the $327 billion US diabetes market. MedWatch will pay an annual fee of US$120,000 plus a 2% royalty on gross sales, projected to be US$5.00 to US$8.00 per device. The agreement has an initial term of 7 years with automatic renewals and includes a US$2 million early termination fee. This strategic partnership aims to enhance diabetes management through innovative blood glucose monitoring solutions.
FAQ
What is the current stock price of AI / ML Innovations (AIMLF)?
What is the market cap of AI / ML Innovations (AIMLF)?
What does AI/ML Innovations Inc. do?
What is 'Follow Your Heart'?
What are the key features of The Pulse Guru?
What recent acquisitions has AI/ML Innovations Inc. made?
What is NeuralCloud Solutions Incorporated?
How does AI/ML Innovations Inc. plan to expand its market presence?
Where can I buy AI/ML Innovations Inc. products?
What is the Neural Net Store?
How does AI/ML Innovations Inc. support the healthcare industry?
What is the significance of the Long ECG Neural Net?
